Trial reportRespiratory research2019
Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial.
Trial report in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02088216 (Effect of N-acetylcysteine on Exacerbations of Bronchiectasis), which is not on this map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of N-acetylcysteine on Exacerbations of Bronchiectasis (BENE): a Randomized Controlled Trial
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Mucoactive agents in bronchiectasis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Management of Adult Bronchiectasis: Consensus-Based Guidelines of the German Respiratory Society.Respiration; international review of thoracic diseases · 2026Guideline
- Prevalence of bronchiectasis in adults: a meta-analysis.BMC public health · 2024Pooled it
- A systematic literature review of the clinical and socioeconomic burden of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Airway Clearance and Pediatric Pulmonary Rehabilitation in Primary Ciliary Dyskinesia: A Clinical Framework for Children and Adolescents.Journal of clinical medicine · 2026Review
- Review
- N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR).Frontiers in medicine · 2026Review
- Global research trends and hotspots in bronchiectasis: a bibliometric analysis.Journal of thoracic disease · 2025Article
- What is the optimal dose of N-acetylcysteine in adult patients with bronchiectasis?-data from the RIBRON registry.Journal of thoracic disease · 2025Article
- Non-cystic fibrosis bronchiectasis in Taiwan.BMJ open respiratory research · 2025Observational
- Anti-Inflammatory and Anti-Oxidant Properties of N-Acetylcysteine: A Fresh Perspective.Journal of clinical medicine · 2024Review
- Exacerbations of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Neutrophil Extracellular Traps and Respiratory Disease.Journal of clinical medicine · 2024Review
- Hospital admission rates and related outcomes among adult Aboriginal australians with bronchiectasis - a ten-year retrospective cohort study.BMC pulmonary medicine · 2024Article
- Clinical efficacy of budesonide combined with acetylcysteine in the treatment of mycoplasma pneumonia infection.Immunity, inflammation and disease · 2023Article
- Exacerbation Prevention and Management of Bronchiectasis.Tuberculosis and respiratory diseases · 2023Article
- Neutrophil Extracellular Traps in Airway Diseases: Pathological Roles and Therapeutic Implications.International journal of molecular sciences · 2023Review
- Insights into Personalised Medicine in Bronchiectasis.Journal of personalized medicine · 2023Review
- Octreotide as a novel agent for the management of bronchorrhea in mechanically ventilated patients: A case series and review of literature.Respiratory medicine case reports · 2023Article
- The effect of N-acetylcysteine in patients with non-cystic fibrosis bronchiectasis (NINCFB): study protocol for a multicentre, double-blind, randomised, placebo-controlled trial.BMC pulmonary medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundN-acetylcysteine is a classic mucolytic agent. This study aimed to investigate the efficacy of N-acetylcysteine on reducing the risk of exacerbations in bronchiectasis patients.
methodsA prospective, randomized, controlled trial was conducted between April 1, 2014 and December 31, 2016 in five general hospitals in Shandong Province, China. Adult bronchiectasis patients with at least two exacerbations in the past year were potentially eligible. Patients were randomly assigned to receive oral N-acetylcysteine (600 mg, twice daily, 12 months) or on-demand treatment.
resultsA total of 161 patients were eligible for randomization (81 to the N-acetylcysteine group and 80 to the control group). During the 12-month follow-up, the incidence of exacerbations in the N-acetylcysteine group was significantly lower than that in the control group (1.31 vs. 1.98 exacerbations per patient-year; risk ratio, 0.41; 95% CI, 0.17-0.66; P = 0.0011). The median number of exacerbations in the N-acetylcysteine group was 1 (0.5-2), compared with 2 (1-2) in the control group (U = - 2.95, P = 0.003). A total of 24.7% of the N-acetylcysteine group patients and 11.3% of the control group patients remained exacerbation-free throughout the 12-month follow-up (χ
conclusionThe long-term use of N-acetylcysteine is able to reduce the risk of exacerbations for bronchiectasis patients in Shandong Province, China. The results of this study should be verified in a larger randomized controlled trial.
trial registrationClinicalTrials.gov (NCT02088216) (Registered date: March 5, 2014).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.